Gautam R. Shroff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gautam R. Shroff has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
- Charles A. Herzog
Division of Cardiology, Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota; and
14 shared publications Charles A. Herzog
Cardiology Division, Department of Internal Medicine, Hennepin Healthcare University of Minnesota Minneapolis Minnesota USA
13 shared publicationsCraig A. Solid
Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, Minnesota, USA
6 shared publications- Charles A. Herzog
Department of Medicine, Hennepin County Medical Center and University of Minnesota, Minneapolis, MN
4 shared publications - Fredrick Ogugua
Hennepin Healthcare, Minneapolis, MN, USA
4 shared publications - Michael Cheung
KDIGO, Brussels, Belgium
4 shared publications
Latest Publications
- 24 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Evidence-Based Cardiovascular–Kidney–Metabolic Therapies in Kidney Transplant Recipients
Pivotal clinical trials have heralded several new classes of pharmacologic agents focused on improving combined heart–kidney outcomes among patients with cardiovascular–kidney–metabolic syndrome. This review compiles the current evidence pertaining to the use of these novel, exciting classes of agents among kidney transplant recipients (KTRs). Treatment with renin–angiotensin–aldosterone system inhibitors continues to remain the backbone of pharmacologic management among KTRs for several indications. Data from systematic reviews and meta-analyses support the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists with several comorbidities. However, evidence for both nonsteroidal and steroidal mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors is emerging and not adequate to support routine clinical use in KTRs. Finally, data from randomized controlled trials on statins serve as a reminder of their impact in the metabolic milieu following kidney transplantation. Using the recently introduced paradigm of cardiovascular–kidney–metabolic syndrome, this review proposes that four pharmacologic agents constitute the key pillars for improving downstream heart–kidney outcomes on the basis of existing evidence: renin–angiotensin–aldosterone system inhibitors, statins, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists. Furthermore, this review highlights relevant practical drug interactions with immunosuppressants and considerations of tolerability of these agents among KTRs. Finally, this review discusses specific management considerations for coronary heart disease, heart failure, and atrial fibrillation with unique nuances applicable to KTRs. There remains a critical need for randomized trials in this vulnerable population focused on improvement in combined heart–kidney outcomes.
- 24 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Evidence-Based Cardiovascular–Kidney–Metabolic Therapies in Kidney Transplant Recipients
Pivotal clinical trials have heralded several new classes of pharmacologic agents focused on improving combined heart–kidney outcomes among patients with cardiovascular–kidney–metabolic syndrome. This review compiles the current evidence pertaining to the use of these novel, exciting classes of agents among kidney transplant recipients (KTRs). Treatment with renin–angiotensin–aldosterone system inhibitors continues to remain the backbone of pharmacologic management among KTRs for several indications. Data from systematic reviews and meta-analyses support the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists with several comorbidities. However, evidence for both nonsteroidal and steroidal mineralocorticoid receptor antagonists and angiotensin receptor-neprilysin inhibitors is emerging and not adequate to support routine clinical use in KTRs. Finally, data from randomized controlled trials on statins serve as a reminder of their impact in the metabolic milieu following kidney transplantation. Using the recently introduced paradigm of cardiovascular–kidney–metabolic syndrome, this review proposes that four pharmacologic agents constitute the key pillars for improving downstream heart–kidney outcomes on the basis of existing evidence: renin–angiotensin–aldosterone system inhibitors, statins, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists. Furthermore, this review highlights relevant practical drug interactions with immunosuppressants and considerations of tolerability of these agents among KTRs. Finally, this review discusses specific management considerations for coronary heart disease, heart failure, and atrial fibrillation with unique nuances applicable to KTRs. There remains a critical need for randomized trials in this vulnerable population focused on improvement in combined heart–kidney outcomes.
- Top Cited PapersOpen Access
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e047458
Heart–Brain Axis: Subclinical Cardiovascular Changes and Brain Health
Complex bidirectional interactions between the nervous and cardiovascular systems are integrated through the heart–brain axis, a physiological pathway that governs both neural regulation of cardiovascular function and cardiovascular influences on brain health. Emerging evidence indicates that even in the absence of overt disease, subclinical changes in the heart, aortic arch, and extracranial arteries contribute to brain injury and cognitive vulnerability. This review synthesizes current knowledge on how subclinical heart–brain axis dysfunction affects brain structure and function, highlighting the roles of central and autonomic neural pathways as well as hormonal signaling in driving neurological decline. Key biomarkers linked to silent brain injury, cognitive decline, and dementia are discussed, emphasizing their potential for early risk stratification and as targets for preventive interventions. We also outline mechanistic pathways connecting subclinical heart–brain axis dysfunction to adverse brain outcomes, identify major gaps in current evidence, and propose priorities for future research and clinical trials aimed at early detection and risk reduction to preserve brain health.
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e047458
Top Cited PapersOpen AccessHeart–Brain Axis: Subclinical Cardiovascular Changes and Brain Health
Complex bidirectional interactions between the nervous and cardiovascular systems are integrated through the heart–brain axis, a physiological pathway that governs both neural regulation of cardiovascular function and cardiovascular influences on brain health. Emerging evidence indicates that even in the absence of overt disease, subclinical changes in the heart, aortic arch, and extracranial arteries contribute to brain injury and cognitive vulnerability. This review synthesizes current knowledge on how subclinical heart–brain axis dysfunction affects brain structure and function, highlighting the roles of central and autonomic neural pathways as well as hormonal signaling in driving neurological decline. Key biomarkers linked to silent brain injury, cognitive decline, and dementia are discussed, emphasizing their potential for early risk stratification and as targets for preventive interventions. We also outline mechanistic pathways connecting subclinical heart–brain axis dysfunction to adverse brain outcomes, identify major gaps in current evidence, and propose priorities for future research and clinical trials aimed at early detection and risk reduction to preserve brain health.
- Open Access
- 30 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101837
Valvuloarterial Impedance in End-Stage Kidney Disease Patients With Aortic Stenosis
- 30 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101837
Open AccessValvuloarterial Impedance in End-Stage Kidney Disease Patients With Aortic Stenosis
- 15 May 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 86 (2) , 178-191.e1
Inflammatory and Cardiovascular Events in CKD: The Multi-Ethnic Study of Atherosclerosis (MESA)
- 15 May 2025
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 86 (2) , 178-191.e1
Inflammatory and Cardiovascular Events in CKD: The Multi-Ethnic Study of Atherosclerosis (MESA)
Risk and management of cardiac disease in kidney and liver transplant recipients
Organ transplantation is the treatment of choice for individuals with kidney failure requiring kidney replacement therapy, as well as for those with end-stage liver disease. Despite the significant reduction in long-term morbidity and mortality with transplantation, kidney and liver allograft recipients remain at high risk for cardiovascular disease (CVD) and premature death from cardiovascular causes. This heightened risk is represented across all phenotypes of CVD, including coronary heart disease, heart failure, arrhythmias, valvulopathies and pulmonary hypertension. Pre-existing vascular risk factors for CVD, coupled with superimposed cardiovascular-kidney-metabolic derangements after transplantation, driven at least in part by post-transplant weight gain, immunosuppressive therapies and de novo risk factors such as dyslipidaemia and diabetes, coalesce to increase total CVD risk. In this review, we summarise pathophysiological considerations for both the short- and long-term increase in CVD risk following kidney/liver transplantation. We review the different phenotypes of CVD, with unique considerations for post-transplant care in this patient population. Finally, we highlight the need for awareness about long-term CVD risk and a multidisciplinary approach to managing organ-specific CVD risk in kidney and liver transplant patients.
Risk and management of cardiac disease in kidney and liver transplant recipients
Organ transplantation is the treatment of choice for individuals with kidney failure requiring kidney replacement therapy, as well as for those with end-stage liver disease. Despite the significant reduction in long-term morbidity and mortality with transplantation, kidney and liver allograft recipients remain at high risk for cardiovascular disease (CVD) and premature death from cardiovascular causes. This heightened risk is represented across all phenotypes of CVD, including coronary heart disease, heart failure, arrhythmias, valvulopathies and pulmonary hypertension. Pre-existing vascular risk factors for CVD, coupled with superimposed cardiovascular-kidney-metabolic derangements after transplantation, driven at least in part by post-transplant weight gain, immunosuppressive therapies and de novo risk factors such as dyslipidaemia and diabetes, coalesce to increase total CVD risk. In this review, we summarise pathophysiological considerations for both the short- and long-term increase in CVD risk following kidney/liver transplantation. We review the different phenotypes of CVD, with unique considerations for post-transplant care in this patient population. Finally, we highlight the need for awareness about long-term CVD risk and a multidisciplinary approach to managing organ-specific CVD risk in kidney and liver transplant patients.
- Open Access
- 3 March 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (4) , 101640
Chronic Inflammatory-Related Disease and Cardiovascular Disease in MESA
- 3 March 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (4) , 101640
Open AccessChronic Inflammatory-Related Disease and Cardiovascular Disease in MESA
- Open Access
- 1 October 2024
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 1 (1)
Evaluation and management of aortic stenosis in chronic kidney disease
The combination of aortic stenosis (AS) and chronic kidney disease (CKD) represents a formidable clinical challenge commonly encountered in practice. Specific guidelines addressing the management of AS in CKD/end-stage kidney disease (ESKD) patients are lacking. This review addresses the unique epidemiological features, caveats relevant to diagnostic modalities and specific management considerations pertinent for AS in patients with CKD/ESKD. Transthoracic echocardiography remains the imaging modality of choice for establishing an accurate diagnosis and assessing severity of AS in this population. However, the presence of anatomical and hemodynamic alterations along with co-prevalent valve disease often necessitates complementary imaging including dobutamine stress echocardiography, cardiac computed tomography and magnetic resonance imaging. Management includes blood pressure control, addressing CKD-related metabolic bone disease, and the selection of optimal dialysis modality. For aortic valve replacement (AVR), the choice between mechanical versus biological prosthesis, as well as between surgical versus transcatheter approaches requires careful consideration of patient-specific factors, including life expectancy, bleeding risk, risk of acute kidney injury; as well as prosthesis specific considerations including durability and need for long-term anticoagulation. Patients with CKD/ESKD encounter higher periprocedural risks as well as worse long-term outcomes; yet AVR is associated with improved survival compared to conservative management. Shared-decision making with the patient is essential regarding choice of prosthesis. A multidisciplinary heart-kidney team is recommended for optimizing perioperative planning, hemodynamic/volume status and preventing acute kidney injury to ensure a balanced and comprehensive patient-centered strategy for managing AS in the context of CKD/ESKD.
- 1 October 2024
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 1 (1)
Open AccessEvaluation and management of aortic stenosis in chronic kidney disease
The combination of aortic stenosis (AS) and chronic kidney disease (CKD) represents a formidable clinical challenge commonly encountered in practice. Specific guidelines addressing the management of AS in CKD/end-stage kidney disease (ESKD) patients are lacking. This review addresses the unique epidemiological features, caveats relevant to diagnostic modalities and specific management considerations pertinent for AS in patients with CKD/ESKD. Transthoracic echocardiography remains the imaging modality of choice for establishing an accurate diagnosis and assessing severity of AS in this population. However, the presence of anatomical and hemodynamic alterations along with co-prevalent valve disease often necessitates complementary imaging including dobutamine stress echocardiography, cardiac computed tomography and magnetic resonance imaging. Management includes blood pressure control, addressing CKD-related metabolic bone disease, and the selection of optimal dialysis modality. For aortic valve replacement (AVR), the choice between mechanical versus biological prosthesis, as well as between surgical versus transcatheter approaches requires careful consideration of patient-specific factors, including life expectancy, bleeding risk, risk of acute kidney injury; as well as prosthesis specific considerations including durability and need for long-term anticoagulation. Patients with CKD/ESKD encounter higher periprocedural risks as well as worse long-term outcomes; yet AVR is associated with improved survival compared to conservative management. Shared-decision making with the patient is essential regarding choice of prosthesis. A multidisciplinary heart-kidney team is recommended for optimizing perioperative planning, hemodynamic/volume status and preventing acute kidney injury to ensure a balanced and comprehensive patient-centered strategy for managing AS in the context of CKD/ESKD.
- Open Access
- 17 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (18) , e034527
Work Environment, Burnout, and Intent to Leave Current Job Among Cardiologists and Cardiology Health Care Workers: Results From the National Coping With COVID Survey
Background: Little is known about factors contributing to burnout and intent to leave in cardiologists and other cardiology health care workers. Methods and Results: The Coping With COVID survey assessed work conditions, burnout, and intent to leave among physicians, nurses, advanced practice providers, and other clinical staff (OCS) from April 2020 to December 2020. Single‐item measures assessed work conditions, burnout (emotional exhaustion), and intent to leave. Multilevel logistic regression examined work life variables' relationships to burnout among role types and feeling valued as a mediator. Open‐ended comments analyzed via grounded theory contributed to a conceptual model. Coping With COVID was completed by 1199 US cardiology health care workers (354 physician/520 nurses/198 advanced practice providers/127 OCS). Nurses were most likely to report burnout (59% nurses, 57% OCS, 46% advanced practice providers, 40% physicians, P P sP s≤0.001). Feeling valued was related to lower burnout in most groups. Intent to leave was common (23%–45%) and was lower in physicians and advanced practice providers who felt valued (aORs, 0.26 and 0.22, respectively; P s<0.05). Burnout was highest for nurses in practice 16 to 20 years, and intent to leave was highest for OCS in practice 16 to 20 years. Themes contributing to burnout included personal and patient safety, leadership, and financial issues. Conclusions: Burnout was prevalent among cardiology health care workers and highest in nurses and OCS. Addressing factors associated with burnout in different role types may improve work life sustainability for all cardiology health care workers.
- 17 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (18) , e034527
Open AccessWork Environment, Burnout, and Intent to Leave Current Job Among Cardiologists and Cardiology Health Care Workers: Results From the National Coping With COVID Survey
Background: Little is known about factors contributing to burnout and intent to leave in cardiologists and other cardiology health care workers. Methods and Results: The Coping With COVID survey assessed work conditions, burnout, and intent to leave among physicians, nurses, advanced practice providers, and other clinical staff (OCS) from April 2020 to December 2020. Single‐item measures assessed work conditions, burnout (emotional exhaustion), and intent to leave. Multilevel logistic regression examined work life variables' relationships to burnout among role types and feeling valued as a mediator. Open‐ended comments analyzed via grounded theory contributed to a conceptual model. Coping With COVID was completed by 1199 US cardiology health care workers (354 physician/520 nurses/198 advanced practice providers/127 OCS). Nurses were most likely to report burnout (59% nurses, 57% OCS, 46% advanced practice providers, 40% physicians, P P sP s≤0.001). Feeling valued was related to lower burnout in most groups. Intent to leave was common (23%–45%) and was lower in physicians and advanced practice providers who felt valued (aORs, 0.26 and 0.22, respectively; P s<0.05). Burnout was highest for nurses in practice 16 to 20 years, and intent to leave was highest for OCS in practice 16 to 20 years. Themes contributing to burnout included personal and patient safety, leadership, and financial issues. Conclusions: Burnout was prevalent among cardiology health care workers and highest in nurses and OCS. Addressing factors associated with burnout in different role types may improve work life sustainability for all cardiology health care workers.
- 19 December 2023
- Published by Wiley in Echocardiography
- Vol. 41 (1)
Impact of arteriovenous fistula on flow states in the evaluation of aortic stenosis among ESKD patients on dialysis
Introduction: An arteriovenous fistula (AVF) in patients with end‐stage kidney disease (ESKD) can influence flow states. We sought to evaluate if assessment of aortic stenosis (AS) by transthoracic echocardiographic (TTE) differs in the presence of AVF compared to other dialysis accesses in patients on dialysis.Methods: We identified consecutive ESKD patients on dialysis and concomitant AS from a single center between January 2000 and March 2021. We analyzed TTE parameters of AS severity (velocities, gradients, aortic valve area [AVA]) and hemodynamics (cardiac output [CO], valvuloarterial impedance [Zva]) and compared AS parameters in patients with AVF versus other dialysis access.Results: The cohort included 94 patients with co‐prevalent ESKD and AS; mean age 66 years, 71% male; 43% Black, 24% severe AS. Dialysis access: 53% AVF, 47% others. In the overall cohort, no significant differences were noted between AVF versus non‐AVF in AVA/CO/Zva, but with notable subgroup differences. In mild AS, CO was significantly higher in AVF versus non‐AVF (6.3 vs. 5.2 L/min; p = .04). In severe AS, Zva was higher in the AVF versus non‐AVF (4.6 vs. 3.6 mm Hg/mL/m2). With increasing AS severity in the AVF group, CO decreased, coupled with increase in Zva, likely counterbalancing the net hemodynamic impact of the AVF.Conclusion: Among ESKD patients with AS, TTE parameters of flow states and AS severity differed in those with AVF versus other dialysis accesses and varied with progression in severity of AS. Future longitudinal assessment of hemodynamic parameters in a larger cohort of co‐prevalent ESRD and AS would be valuable.
- 19 December 2023
- Published by Wiley in Echocardiography
- Vol. 41 (1)
Impact of arteriovenous fistula on flow states in the evaluation of aortic stenosis among ESKD patients on dialysis
Introduction: An arteriovenous fistula (AVF) in patients with end‐stage kidney disease (ESKD) can influence flow states. We sought to evaluate if assessment of aortic stenosis (AS) by transthoracic echocardiographic (TTE) differs in the presence of AVF compared to other dialysis accesses in patients on dialysis.Methods: We identified consecutive ESKD patients on dialysis and concomitant AS from a single center between January 2000 and March 2021. We analyzed TTE parameters of AS severity (velocities, gradients, aortic valve area [AVA]) and hemodynamics (cardiac output [CO], valvuloarterial impedance [Zva]) and compared AS parameters in patients with AVF versus other dialysis access.Results: The cohort included 94 patients with co‐prevalent ESKD and AS; mean age 66 years, 71% male; 43% Black, 24% severe AS. Dialysis access: 53% AVF, 47% others. In the overall cohort, no significant differences were noted between AVF versus non‐AVF in AVA/CO/Zva, but with notable subgroup differences. In mild AS, CO was significantly higher in AVF versus non‐AVF (6.3 vs. 5.2 L/min; p = .04). In severe AS, Zva was higher in the AVF versus non‐AVF (4.6 vs. 3.6 mm Hg/mL/m2). With increasing AS severity in the AVF group, CO decreased, coupled with increase in Zva, likely counterbalancing the net hemodynamic impact of the AVF.Conclusion: Among ESKD patients with AS, TTE parameters of flow states and AS severity differed in those with AVF versus other dialysis accesses and varied with progression in severity of AS. Future longitudinal assessment of hemodynamic parameters in a larger cohort of co‐prevalent ESRD and AS would be valuable.
- Open Access
- 23 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1162-1176
Proportional troponin changes and risk for outcomes with intervention strategies in non‐ST‐elevation acute coronary syndrome across kidney function
Aims: This analysis evaluates whether proportional serial cardiac troponin (cTn) change predicts benefit from an early versus delayed invasive, or conservative treatment strategies across kidney function in non‐ST‐elevation acute coronary syndrome (NSTE‐ACS).Methods: Patients diagnosed with NSTE‐ACS in the Veterans Health Administration between 1999 and 2022 were categorized into terciles (80%) of proportional change in serial cTn. Primary outcome included mortality or rehospitalization for myocardial infarction at 6 and 12 months, in survivors of index admission. Adjusted hazard ratio (HR) with 95% confidence Intervals (95% confidence interval [CI]) were calculated for the primary outcome for an early invasive (≤24 h of the index admission), delayed invasive (>24 h of index admission to 90‐days postdischarge), or a conservative management.Results: Chronic kidney disease (CKD) was more prevalent (45.3%) in the lowest versus 42.2% and 43% in middle and highest terciles, respectively (p < 0.001). Primary outcome is more likely for conservative versus early invasive strategy at 6 (HR: 1.44, 95% CI: 1.37–1.50) and 12 months (HR: 1.44, 95% CI: 1.39–1.50). A >80% proportional change demonstrated HR (95% CI): 0.90 (0.83–0.97) and 0.93 (0.88–1.00; p = 0.041) for primary outcome at 6 and 12 months, respectively, when an early versus delayed invasive strategy was used, across CKD stages.Conclusions: Overall, the invasive strategy was safe and associated with improved outcomes across kidney function in NSTE‐ACS. Additionally, >80% proportional change in serial troponin in NSTE‐ACS is associated with benefit from an early versus a delayed invasive strategy regardless of kidney function. These findings deserve confirmation in randomized controlled trials.
- 23 October 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 102 (7) , 1162-1176
Open AccessProportional troponin changes and risk for outcomes with intervention strategies in non‐ST‐elevation acute coronary syndrome across kidney function
Aims: This analysis evaluates whether proportional serial cardiac troponin (cTn) change predicts benefit from an early versus delayed invasive, or conservative treatment strategies across kidney function in non‐ST‐elevation acute coronary syndrome (NSTE‐ACS).Methods: Patients diagnosed with NSTE‐ACS in the Veterans Health Administration between 1999 and 2022 were categorized into terciles (80%) of proportional change in serial cTn. Primary outcome included mortality or rehospitalization for myocardial infarction at 6 and 12 months, in survivors of index admission. Adjusted hazard ratio (HR) with 95% confidence Intervals (95% confidence interval [CI]) were calculated for the primary outcome for an early invasive (≤24 h of the index admission), delayed invasive (>24 h of index admission to 90‐days postdischarge), or a conservative management.Results: Chronic kidney disease (CKD) was more prevalent (45.3%) in the lowest versus 42.2% and 43% in middle and highest terciles, respectively (p < 0.001). Primary outcome is more likely for conservative versus early invasive strategy at 6 (HR: 1.44, 95% CI: 1.37–1.50) and 12 months (HR: 1.44, 95% CI: 1.39–1.50). A >80% proportional change demonstrated HR (95% CI): 0.90 (0.83–0.97) and 0.93 (0.88–1.00; p = 0.041) for primary outcome at 6 and 12 months, respectively, when an early versus delayed invasive strategy was used, across CKD stages.Conclusions: Overall, the invasive strategy was safe and associated with improved outcomes across kidney function in NSTE‐ACS. Additionally, >80% proportional change in serial troponin in NSTE‐ACS is associated with benefit from an early versus a delayed invasive strategy regardless of kidney function. These findings deserve confirmation in randomized controlled trials.